Related Experiment Video
Updated: Dec 18, 2025

A Protocol for Explant Cultures of IDH1-mutant Diffuse Low-grade Gliomas
Published on: May 9, 2025
Differentiating the Differentiation Syndrome Associated with IDH Inhibitors in AML
1Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina. Joshua_Zeidner@med.unc.edu.
Abstract:
Isocitrate dehydrogenase (IDH) inhibitors have clinical activity in acute myeloid leukemia, in part, by differentiating blasts to mature myeloid cells. In the largest systematic analysis to date, differentiation syndrome was seen in 19% of patients treated with IDH inhibitors. Early recognition with uniform diagnostic criteria, as utilized in acute promyelocytic leukemia, may reduce subsequent complications.See related article by Norsworthy et al., p. 4280.
Related Concept Videos
Differentiation of Common Myeloid Progenitor Cells
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
iPS Cell Differentiation
Immunodeficiency Diseases
There are three main causes of immunodeficiency...

